Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline

Jorge  Rico Fontalvo; Juan David  Montejo Hernández; Rodrigo  Daza Arnedo; Jose Cabrales

doi:10.22265/acnef.9.3.602

Vol. 9 No. 3 (2022), Letter to the editor

Vol. 9 No. 3 (2022)

Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline

Letter to the editor

https://doi.org/10.22265/acnef.9.3.602

Published 2022-10-26

Jorge Rico Fontalvo⁺⁻
Juan David Montejo Hernández⁺⁻
Rodrigo Daza Arnedo⁺⁻
Jose Cabrales⁺⁻

Jorge Rico Fontalvo

Colombian Association of Nephrology and Arterial Hypertension, Bogotá, Colombia

https://orcid.org/0000-0002-2852-1241

Juan David Montejo Hernández

Colombian Association of Nephrology and Arterial Hypertension, Bogotá, Colombia

https://orcid.org/0000-0003-3263-3331

Rodrigo Daza Arnedo

Colombian Association of Nephrology and Arterial Hypertension, Bogotá, Colombia

https://orcid.org/0000-0002-6295-4972

Jose Cabrales

Stanford University, Stanford (California), USA

https://orcid.org/0000-0001-5142-8216

PDF

XML-JATS

Keywords

Diabetes Mellitus
Diabetic Nephropathies
obesity
risk factors.
Kidney Diseases

How to Cite

1.

Rico Fontalvo J, Montejo Hernández JD, Daza Arnedo R, Cabrales J. Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline . Rev. Colomb. Nefrol. [Internet]. 2022 Oct. 26 [cited 2024 Dec. 11];9(3). Available from: https://revistanefrologia.org/index.php/rcn/article/view/602

Abstract

Obesity is a risk factor for the development and progression of CKD, which has been shown in numerous studies. The mechanism of how this occurs is not completely understood, but several putative mechanisms proposed via adiposity, include low adiponectin high leptin and resistin, causing inflammation, insulin resistance, RAAS activation and oxidative stress, leading to CKD; in addition, it also causes diabetes mellitus, hypertension, and cardiovascular disease. Obesity is a persistent inflammatory state, and inflammation has been shown to play an important role in the development and progression of diabetic kidney disease, hence controlling obesity has become a key component as a preventative strategy in the development of kidney disease.

https://doi.org/10.22265/acnef.9.3.602

PDF

XML-JATS

References

Kovesdy CP, Furth SL, Zoccali C. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Canadian Journal of Kidney Health and Disease. 2017; 4. https://doi.org/10.1177/2054358117698669

Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular Mechanisms of Diabetic Kidney

Disease. Int. J. Mol. Sci. 2022;2: 8668. https://doi.org/10.3390/ijms23158668

Mottl A, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, et al. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis 2022;79(4):457-479. https://doi.org/10.1053/j.ajkd.2021.09.010

Van der Aart-van der Beek AB, Clegg LE, Penland RC, Boulton DW, Sjostrom CD Mentz RJ, et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes Metab 2020;22: https://doi.org/10.1111/dom.14175

Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, et al. Prediction and validation of exenatide risk marker effects on progression of renal disease: insights from EXSCEL. Diabetes Obes Metab 2020;22(5): 798-806. https://doi.org/10.1111/dom.13958

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. AMPLITUDE-O Trials Investigator. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385(10):896-907. https://doi.org/10.1056/nejmoa2108269

Leoncini, G.; Russo, E.; Bussalino, E.; Barnini, C.; Viazzi, F.; Pontremoli, R. SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. Int. J. Mol. Sci. 2021;22(9):4441. https://doi.org/10.3390/ijms22094441

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. https://doi.org/10.1056/nejmoa2024816

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions

PlumX

Downloads

Download data is not yet available.

Most read articles by the same author(s)

José Correa Guerrero, Jorge Rico Fontalvo, Rodrigo Daza Arnedo, Emilio Abuabara Franco, Victor Leal Martínez, Nehomar Eduardo Pájaro Galvis, María Cardona Blanco, María Monterrosa Robles, Jenniffer Palomino Herrera, Mauricio Batista Lambis, Isaias Garcerant Campo, Ronald Castro Ahumada, Karen Perales Caballero, Acid-base imbalance: a review with proposed unified diagnostic algorithm , Revista Colombiana de Nefrología: Vol. 7 No. 2 (2020): July - December 2020
María Monterrosa Robles, Jorge Rico Fontalvo, Rodrigo Daza Arnedo, José Pérez Olivo, María Cardona Blanco , Nehomar Eduardo Pájaro Galvis, Christian Pérez Calvo, Lacides Caparroso Ramos, Victor Leal Martínez, Emilio Abuabara Franco, Isabella Uparella Gulfo, María Mendoza García, José Correa Guerrero, Acute kidney injury in pregnant women , Revista Colombiana de Nefrología: Vol. 8 No. 1 (2021): Continuous publication
Christian Pérez Calvo, Jorge Rico Fontalvo, Oscar Lavalle López, Rodrigo Daza Arnedo, Nehomar Pájaro Galvis, María Monterrosa Robles, Jose Pérez Olivo, Victor Leal Martínez, Emilio Abuabara Franco, Roberto Benavides Arenas, María Cardona Blanco , Isabella Uparella Gulfo, Mario Vengoechea Visbal, Chronic kidney disease in pregnant women , Revista Colombiana de Nefrología: Vol. 8 No. 1 (2021): Continuous publication
César Mercado Ferrer, Emilio Rey Vela, Jorge Rico Fontalvo, Rodrigo Daza Arnedo, Nehomar Eduardo Pájaro Galvis, Greisy González, Jaime Gómez Ayala, Victor Leal Martínez, Emilio Abuabara Franco, Alonso Pomares Lara, Christian Pérez Calvo, María Raad Sarabia, Hemoperfusion with the Cytosorb device in a patient with severe COVID-19 , Revista Colombiana de Nefrología: Vol. 8 No. 1 (2021): Continuous publication
Edwin Silva Monsalve, Gustavo Eduardo Roncancio Villamil, Jessica Forero, Juan Gonzalo Mesa, Juan Guillermo Cárdenas Aguilera, Mayra Estévez, Richard Baquero Rodríguez, Martha Carrascal, Claudia Patricia Beltrán Arroyave, Nancy Yomayusa González, Jorge Rico Fontalvo, Gustavo Aroca, Kelly Rocío Chacón Acevedo, Germán Camacho Moreno, María José López Mora, Carlos Guillermo Garcés Samudio, Jorge Alberto Cortés, Iván Felipe Gutiérrez Tobar, Daniela Torres Hernández, Pio López, María José Soler Romeo, Colombian consensus on vaccination in patients with chronic kidney disease , Revista Colombiana de Nefrología: Vol. 9 No. 3 (2022): Continuous publication
Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Jose Cabrales , Juan Diego Montejo-Hernández, Semaglutide in Overweight and Obese patients: Cardiovascular and/or Renal Metabolic Benefits , Revista Colombiana de Nefrología: Vol. 9 No. 3 (2022): Continuous publication
Jorge Rico Fontalvo, Rodrigo Daza Arnedo, Nataly Aguilar Salcedo, Mercedes Alfaro, Diana Navas Torrejano, María Cardona Blanco, Isabela Uparella Gulfo, Maria Raad Sarabia, Emilio Abuabara Franco, Jose Cabrales, New evidence in the treatment of diabetic kidney disease: what is finerenone’s contribution? , Revista Colombiana de Nefrología: Vol. 9 No. 3 (2022): Continuous publication

Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline

Keywords

How to Cite

Download Citation

Abstract

References

Dimensions

PlumX

Downloads

Most read articles by the same author(s)